Skip to content

Randomozed,Blinded, placebo controlled, clinical study to evaluate the efficacy of Dabur Babool Neem Toothpaste DRDC/PC/8003 in oral hygeine and dental care

A Double blind, randomized, placebo controlled, clinical study to evaluate the efficacy of a Dabur Babool Neem Toothpaste DRDC/PC/8003 in oral hygeine and dental care

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/12/007529
Enrollment
50
Registered
2016-12-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K051- Chronic gingivitis Health Condition 2: K053- Chronic periodontitis

Interventions

Intervention1: Dabur Babool Neem Toothpaste (DRDC/PC/8003): Subject were advised to brush with Babool Neem Toothpaste two times a day for 12 week Control Intervention1: Placebo: Subjects were advised

Sponsors

Dabur India Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Periodontitis & Gingival Group: 1. Subjects of both sexes in the age groups of 18-45 yrs 2. Subjects willing to sign informed consent form 3. Subjects who have at least 20 natural uncrowned teeth excluding third molars. 4. Subjects with periodontitis and gingivitis 5. Subjects with ability to comply with all study requirements. 6. Subjects having gingivitis with gingival index > 1 at more than 60 % of sites examined. 7. Subjects with tooth stains. 8. Subjects having dental plaque with plaque index of 2 or more. Healthy Group: 1. Healthy subjects of both sexes in the age group of 18 to 45 years. 2. Subjects willing to sign informed consent form. 3. Subjects who have at least 20 natural uncrowned teeth excluding third molars. 4. Subjects with ability to comply with all study requirements.

Exclusion criteria

Exclusion criteria: Periodontitis & Gingival Group: 1. Subjects having pain and multiplicity of periodontal/gingival problems or advanced generalized chronic inflammatory periodontal disease or any gross oral pathology. 2. Subjects having history of known sensitivity or oral mucosal tissue reaction to toothpaste. 3. Subjects having any serious systemic disease. 4. Subjects with any external dental treatment like scaling, polishing, flossing etc. 5. Subjects with Upper respiratory tract infection, Urinary tract infection, Gastrointestinal Tract infection, Skin infection. 6. Subjects with history of intake of antibiotics and anti-inflammatory drugs for the past 3-4 weeks 7. Subjects with history of fluoride treatment for the past two weeks. 8. Pregnant or lactating mothers. 9. Subjects with involvement in any concurrent study the nature of which may affect the parameters being investigated in the study. 10. Subjects not willing to sign informed consent. 11. Subjects not willing to come for follow-up when required 12. Subjects with presence of relatively severe tetracycline stained teeth. Healthy Group: As per the exclusion criteria for gingivitis & periodontitis group.

Design outcomes

Primary

MeasureTime frame
For GIngivitis & Periodontitis Group: change in scores of gingivitis &/or signs & symptoms, change in microbiologiacl assesment (swab culture), elimination/reduction in malodor if applicable, change in scores of lobene stain &/or signs & symptoms, change in plaque scores &/or signs & symptoms, change in clinivcal attachement loss For Healthy Group: Reduction in microbial counts (swab culture)Timepoint: 12 weeks for gingivits & periodontitis group & 6 weeks for healthy group

Secondary

MeasureTime frame
For GIngivitis & Periodontitis Group: Global patient & Investigator evaluation, ADR/AE profile For Healthy Group: Lobene index, organoleptic index, plaque assesment/plaque index, gingival index, clinical attachment loss, ADR/AE profileTimepoint: 12 weeks for gingivits & periodontitis group & 6 weeks for healthy group

Countries

India

Contacts

Public ContactSunil Kumar

Dabur India ltd.

arun.gupta@dabur.com012033878614

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026